GlassScriptPhysician profile
Michele Hornstein
NPI 1972542256
$10,279.62
in general payments reported to CMS, 2019-2025
37 companies · $936 in 2025
The $936 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $618 · 2020: $892 · 2021: $2,040 · 2022: $1,953 · 2023: $1,735 · 2024: $2,106 · 2025: $936.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,707 · Education: $68.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,707.33 |
| Education | $68.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,140.61 | 2019-2025 | |
| Novo Nordisk INC | $1,427.45 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,378.87 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $1,210.38 | 2019-2025 | Otezla, Repatha, Otezla |
| Lilly USA, LLC | $651.30 | 2019-2024 | Mounjaro, Zepbound, Amyvid |
| Lundbeck LLC | $479.80 | 2022-2024 | Vyepti |
| Biohaven Pharmaceuticals, INC. | $297.79 | 2021 | |
| Novartis Pharmaceuticals Corporation | $277.31 | 2019-2024 | |
| Glaxosmithkline, LLC. | $181.67 | 2019-2025 | Shingrix, Arexvy |
| Otsuka America Pharmaceutical, INC. | $171.04 | 2023-2025 | Rexulti, Nuedexta |
| Pfizer INC. | $164.95 | 2022-2025 | |
| Allergan, INC. | $160.02 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $152.64 | 2022 | |
| Idorsia Pharmaceuticals US INC | $143.29 | 2023 | Quviviq |
| Eisai INC. | $139.02 | 2020-2022 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michele Hornstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.